2026 Global: Acute Myeloid Leukemia Market -Competitive Review (2032) report
Description
The 2026 Global: Acute Myeloid Leukemia Market -Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for acute myeloid leukemia market by geography and historical trend. The scope of the report extends to sizing of the acute myeloid leukemia market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
The acute myeloid leukemia (AML) market features major companies driving innovation through approved therapies, pipeline candidates, and targeted treatments. Leading players include Amgen Inc., Novartis AG, Jazz Pharmaceuticals plc, Pfizer, AbbVie, Bristol Myers Squibb, Astellas Pharma, Roche, Sanofi, and Daiichi Sankyo, which dominate due to their established drugs and ongoing clinical developments. These firms address AML's high unmet needs, particularly in relapsed/refractory cases and genetically defined subtypes like FLT3-mutated AML, with over 110 companies globally advancing more than 120 candidates spanning preclinical to late-stage trials. Amgen's Blincyto (blinatumomab), a bispecific T-cell engager, expands from ALL into AML via immunotherapies targeting leukemia cells, while Novartis's Rydapt (midostaurin) pioneered FLT3 inhibition, now combined with other agents for better survival. Jazz's Vyxeos (CPX-351) offers superior efficacy in high-risk elderly patients, achieving 9.5 months median survival versus 5.9 months for standard chemotherapy.
Pipeline advancements underscore these companies' roles, with AbbVie, Bristol Myers Squibb, and Astellas Pharma leading in combinations like venetoclax-based regimens and antibody-drug conjugates. Roche (F. Hoffmann-La Roche Ltd) excels in diagnostics and biomarkers for personalized medicine, identifying mutations to tailor therapies. Sanofi and Daiichi Sankyo contribute through partnerships and novel agents, while Pfizer and Otsuka bolster the market with supportive oncology portfolios. Emerging leaders like Ryvu Therapeutics develop RVU120, a CDK8/19 inhibitor overcoming resistance, and Actinium Pharmaceuticals advances Actimab-A radiopharmaceuticals for relapsed AML. DelveInsight highlights additional innovators such as BeiGene, Seagen, MacroGenics, and Prelude Therapeutics pushing immunotherapies like Galinpepimut-S and WU-NK-101. Market concentration favors these giants, with Jazz, Novartis, and Amgen reporting pivotal trial successes that expand indications across AML subtypes.
These ten companies shape the AML landscape by integrating precision medicine, CAR-T explorations, and next-generation modalities amid rising prevalence linked to comorbidities. Their efforts, from Vyxeos expansions to FLT3-targeted combos, promise improved outcomes, though challenges like resistance persist. Collaborative pipelines, including those from AstraZeneca and Gilead, further intensify competition, positioning the market for growth through 2025 innovations in transcriptional modulators and NK cell therapies.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for acute myeloid leukemia market by geography and historical trend. The scope of the report extends to sizing of the acute myeloid leukemia market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
The acute myeloid leukemia (AML) market features major companies driving innovation through approved therapies, pipeline candidates, and targeted treatments. Leading players include Amgen Inc., Novartis AG, Jazz Pharmaceuticals plc, Pfizer, AbbVie, Bristol Myers Squibb, Astellas Pharma, Roche, Sanofi, and Daiichi Sankyo, which dominate due to their established drugs and ongoing clinical developments. These firms address AML's high unmet needs, particularly in relapsed/refractory cases and genetically defined subtypes like FLT3-mutated AML, with over 110 companies globally advancing more than 120 candidates spanning preclinical to late-stage trials. Amgen's Blincyto (blinatumomab), a bispecific T-cell engager, expands from ALL into AML via immunotherapies targeting leukemia cells, while Novartis's Rydapt (midostaurin) pioneered FLT3 inhibition, now combined with other agents for better survival. Jazz's Vyxeos (CPX-351) offers superior efficacy in high-risk elderly patients, achieving 9.5 months median survival versus 5.9 months for standard chemotherapy.
Pipeline advancements underscore these companies' roles, with AbbVie, Bristol Myers Squibb, and Astellas Pharma leading in combinations like venetoclax-based regimens and antibody-drug conjugates. Roche (F. Hoffmann-La Roche Ltd) excels in diagnostics and biomarkers for personalized medicine, identifying mutations to tailor therapies. Sanofi and Daiichi Sankyo contribute through partnerships and novel agents, while Pfizer and Otsuka bolster the market with supportive oncology portfolios. Emerging leaders like Ryvu Therapeutics develop RVU120, a CDK8/19 inhibitor overcoming resistance, and Actinium Pharmaceuticals advances Actimab-A radiopharmaceuticals for relapsed AML. DelveInsight highlights additional innovators such as BeiGene, Seagen, MacroGenics, and Prelude Therapeutics pushing immunotherapies like Galinpepimut-S and WU-NK-101. Market concentration favors these giants, with Jazz, Novartis, and Amgen reporting pivotal trial successes that expand indications across AML subtypes.
These ten companies shape the AML landscape by integrating precision medicine, CAR-T explorations, and next-generation modalities amid rising prevalence linked to comorbidities. Their efforts, from Vyxeos expansions to FLT3-targeted combos, promise improved outcomes, though challenges like resistance persist. Collaborative pipelines, including those from AstraZeneca and Gilead, further intensify competition, positioning the market for growth through 2025 innovations in transcriptional modulators and NK cell therapies.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
